论文部分内容阅读
目的：报告Ⅲ期乳腺癌术前联合化疗后的作用。材料和方法：从1982年1月至1992年1月术前以5－FU、CTX、MTX、VCR和强的松联合化疗Ⅲ期乳腺癌56例，化疗后再行手术及放化疗。结果：术前化疗后原发肿瘤明显变小，光镜下见肿瘤组织明显变性、坏死、炎细胞浸润，肿瘤区域内见血管内皮增生、管壁增厚、透明变性和血管闭塞，癌巢间胶原纤维增生及纤维化改变。其5年生存率为70．8％。同期未采用术前化疗Ⅲ期乳腺癌60例，5年生存率为36．6％。二者有明显差异（P<0．01）。结论：术前化疗对改善Ⅲ期乳腺癌的疗效、提高5年生存率具有明显作用。
Objective: To report the effect of preoperative combined chemotherapy on stage III breast cancer. Materials and Methods: From January 1982 to January 1992, 56 patients with stage III breast cancer were treated with 5-FU, CTX, MTX, VCR, and prednisone. After surgery, chemotherapy and radiotherapy and chemotherapy were performed. RESULTS: After the preoperative chemotherapy, the primary tumors became significantly smaller. Under the light microscope, the tumor tissue showed significant degeneration, necrosis, and inflammatory cell infiltration. The vascular endothelial hyperplasia, thickening of the wall, hyaline degeneration, and vascular occlusion were seen in the tumor area. Collagen fibrosis and fibrosis change. The 5-year survival rate was 70.8%. During the same period, 60 patients with stage III breast cancer before surgery were not used, and the 5-year survival rate was 36.6%. There was a significant difference between the two (P<0.01). Conclusion: Preoperative chemotherapy has significant effect on improving the curative effect of stage III breast cancer and improving 5-year survival rate.